Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.01
- Piotroski Score 3.00
- Grade Buy
- Symbol (MRNS)
- Company Marinus Pharmaceuticals, Inc.
- Price $1.76
- Changes Percentage (-4.62%)
- Change -$0.09
- Day Low $1.74
- Day High $1.88
- Year High $11.26
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $3.00
- High Stock Price Target $6.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.64
- Trailing P/E Ratio -0.58
- Forward P/E Ratio -0.58
- P/E Growth -0.58
- Net Income $-141,405,000
Income Statement
Quarterly
Annual
Latest News of MRNS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Great week for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) institutional investors after losing 78% over the previous year
Understanding a stock's ownership structure and analyst forecasts can reveal investment opportunities. Marinus Pharmaceuticals, Inc. is primarily institution-owned, with hedge funds owning 23%. Top sh...
By Yahoo! Finance | 4 days ago -
Marinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts?
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is a biopharmaceutical company focused on treating rare epilepsies. Despite challenges, its potential lies in the growth of its primary asset, ganaxolone. A...
By Yahoo! Finance | 2 months ago
